Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 21500
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very poor margins and returns
Data is available to registered users only
Data is available to registered users only
About
CKD Bio Corp. manufactures and distributes drug substances based on fermentation, synthesis, and biotechnology in South Korea. It offers drug substances in the areas of antibiotic, ß-lactamase inhibitors, immunosuppressants, anticancer drugs, obesity treatment drugs, dry eye, antivirus, antituberculosis, antihyperlipidemics, and probiotics. The company also provides contract research and development, and manufacturing services for active pharmaceutical...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT
Data is available to registered users only
Buy
Sell